DOI:
10.1055/s-00043364
Pharmaceutical Fronts
LinksClose Window
References
Kelly MP, Hickey C, Makonnen S. et al.
Preclinical activity of the novel anti-prolactin receptor (PRLR) antibody-drug conjugate REGN2878-DM1 in PRLR-positive breast cancers.
Mol Cancer Ther 2017;
16 (07) 1299-1311
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.